Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323291 | PMC |
| http://dx.doi.org/10.21037/tau.2018.08.21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study.
Sci Rep
January 2025
Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which treatment is effective as first-line metastatic therapy. This retrospective, multicenter study included 120 patients diagnosed with stage IIIB-IIID melanoma receiving both adjuvant and first-line metastatic treatment between 2007 and 2023.
View Article and Find Full Text PDF[Research progress in neoadjuvant therapy for epithelial ovarian cancer].
Zhonghua Fu Chan Ke Za Zhi
January 2025
[Clinical characteristics and prognosis of ovarian juvenile granulosa cell tumors].
Zhonghua Fu Chan Ke Za Zhi
January 2025
Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing100021, China.
To analyze the clinical characteristics, treatments, and prognosis of patients with ovarian juvenile granulosa cell tumor (JGCT). Clinical and pathological data, and follow-up information of 34 patients diagnosed with JGCT from 2000 to 2021 were collected from the surveillance, epidemiology, and end results (SEER) database. A retrospective analysis was conducted to summarize the patients' clinical and pathological characteristics, treatments, and prognosis.
View Article and Find Full Text PDF[Pathological evaluation of advanced gastric cancer after neoadjuvant chemotherapy].
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing 210029, China.
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).
Int J Radiat Oncol Biol Phys
January 2025
Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
Background: Standard radiotherapy (RT) for locally advanced NSCLC (LA-NSCLC) employs a uniform dose of approximately 60 Gy. Recent trials demonstrated that radiotherapy dose escalation may not improve outcomes and may cause added toxicity. XXX previously performed a single-arm trial testing a personalized, risk-adapted, and de-intensified RT strategy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!